Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 1/20 | 0.53 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.51 |
| ▸ | MAPT | P10636 | 2/20 | 0.46 |
| ▸ | MEN1 | O00255 | 2/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.46 |
| ▸ | ALOX5 | P09917 | 2/20 | 0.45 |
| ▸ | CA2 | P00918 | 1/20 | 0.44 |
| ▸ | IDH1 | O75874 | 1/20 | 0.42 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.40 |
| ▸ | MAOA | P21397 | 1/20 | 0.38 |
| ▸ | MAOB | P27338 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4281466 | 0.94 | CYP3A4 (0.48) | CYP3A4ALDH1A1MAPTMEN1KMT2A | |
| SCHEMBL4288729 | 0.92 | CYP3A4 (0.49) | CYP3A4ALDH1A1MAPTMEN1KMT2A | |
| SCHEMBL4292887 | 0.92 | CYP3A4 (0.49) | CYP3A4ALDH1A1MAPTMEN1KMT2A | |
| SCHEMBL3999055 | 0.92 | CYP3A4 (0.49) | CYP3A4ALDH1A1MAPTMEN1KMT2A | |
| SCHEMBL4287021 | 0.91 | KMT2A (0.50) | CYP3A4ALDH1A1MAPTMEN1KMT2A | |
| SCHEMBL4004352 | 0.90 | CYP3A4 (0.47) | CYP3A4ALDH1A1MAPTMEN1KMT2A | |
| SCHEMBL4289242 | 0.90 | CYP3A4 (0.47) | CYP3A4ALDH1A1MEN1KMT2A | |
| SCHEMBL4292518 | 0.89 | CYP3A4 (0.46) | CYP3A4ALDH1A1MAPTMEN1KMT2A | |
| SCHEMBL4288672 | 0.87 | SLC5A2 (0.46) | CYP3A4ALDH1A1MAPT | |
| SCHEMBL4294675 | 0.87 | CYP3A4 (0.45) | CYP3A4ALDH1A1MAPTMEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-101472937-A | Benzylphenylglucopyranoside Derivatives | DAIICHI SANKYO CO LTD (JP) | 2009-07-01 | — | — | CN | disclosed |
| US-20090137499-A1 | BENZYLPHENYL GLUCOPYRANOSIDE DERIVATIVE | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2009-05-28 | — | — | US | disclosed |
| EP-2048150-A1 | BENZYL PHENYL GLUCOPYRANOSIDE DERIVATIVE | Daiichi Sankyo Company, Limited (JP) | 2009-04-15 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090137499-A1 | BENZYLPHENYL GLUCOPYRANOSIDE DERIVATIVE | SLC5A1, SLC5A2, SLC2A1 | CYP3A4 534/4885ALDH1A1 896/4885MAPT 2884/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.